Showing results (21-30 of 29) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
JTO Clinical and Research Reports|December 23, 2022
Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain MetastasesMarcin Nicoś, Luuk Harbers, Enrico Patrucco, et al.Cancer Discovery|June 22, 2026
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathwayPietro Scaparone, Alessia Mira, Taek-Chin Cheong, et al.Nature Communications|August 30, 2024
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockadeMarie-Julie Nokin, Alessia Mira, Enrico Patrucco, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung CancerBiagio Ricciuti, Jieun Son, Jeffrey J Okoro, et al.Blood Advances|October 9, 2021
Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphomaChiara Pighi, Taek-Chin Cheong, Mara Compagno, et al.Nature Medicine|December 5, 2018
Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphomaMatteo Menotti, Chiara Ambrogio, Taek-Chin Cheong, et al.Science Translational Medicine|June 28, 2023
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphomaCristina Mastini, Marco Campisi, Enrico Patrucco, et al.Nature Cancer|July 10, 2023
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancerInes Mota, Enrico Patrucco, Cristina Mastini, et al.Nature|April 8, 2024
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Bianca J Lee, Jingjing Jiang, et al.Pageof 3